Figure 1: PHD3 is silenced in glioma progression. | Nature Communications

Figure 1: PHD3 is silenced in glioma progression.

From: Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR

Figure 1

(a,b) CAIX expression is enhanced in glioma progression, whereas PHD3 expression is attenuated. qPCR analysis of CAIX (a) and PHD3 (b) gene expression in normal adult brain (NB), diffuse astrocytomas (WHO grade II), anaplastic astrocytomas (WHO grade III), (s)econdary and (p)rimary glioblastomas (WHO grade IV; n=76). (c) PHD3 promoter hypermethylation is an early event in glioma progression. Frequency of PHD3 promoter hypermethylation in NB and gliomas of different grades as determined by methylation-specific PCR. (d,e) PHD3 promoter hypermethylation decreases PHD3 expression. Comparison of PHD3 mRNA levels in gliomas with or without PHD3 promoter methylation as determined in b,c, respectively, within our glioma cohort (d). Comparison of PHD3 mRNA expression in glioblastomas with or without PHD3 promoter methylation from TCGA cohort (n=251, tumours for which methylation data are available) (e). (f) qPCR analysis of PHD3 expression in G55, U118 and HGBM tumour cells with hypermethylated and nonmethylated PHD3 promoter, respectively, ±treatment with the demethylating agent 5-azacytidine (20 μM) for 72 h and Trichostatin A (1 μM) for the last 24 h (n=3). All values are means+s.e.m., *P<0.05; **P<0.01; ***P<0.001.

Back to article page